Center for Drug Evaluation and Research. Biosimilars [Internet]. FDA. FDA; 2023 [cited 2024 Mar 20]. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars.

Rodriguez G, Mancuso J, Lyman GH, Cardoso F, Nahleh Z, Vose JM, et al. ASCO policy statement on biosimilar and interchangeable products in oncology. JCO Oncol Pract. 2023;19:411–9.

Article  PubMed  Google Scholar 

Schiestl M, Krendyukov A. The ESMO Position Paper on biosimilars in oncology: enhancing the provision of accurate education and information. ESMO Open. 2017;2: e000245.

Article  PubMed  PubMed Central  Google Scholar 

Cohen JP, Felix AE, Riggs K, Gupta A. Barriers to market uptake of biosimilars in the US. Generics Biosimilars Initiat J. 2014;3:108–15.

Article  Google Scholar 

Moorkens E, Jonker-Exler C, Huys I, Declerck P, Simoens S, Vulto AG. Overcoming barriers to the market access of biosimilars in the European Union: the case of biosimilar monoclonal antibodies. Front Pharmacol [Internet]. 2016 [cited 2024 Feb 16];7. https://doi.org/10.3389/fphar.2016.00193/abstract.

O’Callaghan J, Barry SP, Bermingham M, Morris JM, Griffin BT. Regulation of biosimilar medicines and current perspectives on interchangeability and policy. Eur J Clin Pharmacol. 2019;75:1–11.

Article  PubMed  Google Scholar 

Fontanillo M, Körs B, Monnard A. Three imperatives for R&D in biosimilars [Internet]. Mckinsey & Company; 2022. https://www.mckinsey.com/industries/life-sciences/our-insights/three-imperatives-for-r-and-d-in-biosimilars#/.

Aitken M. Biosimilars in the United States 2023–2027 [Internet]. IQVIA Institute for Human Data Science; 2023. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/biosimilars-in-the-united-states-2023-2027.

Aitken M. Assessing the Biosimilar Void [Internet]. IQVIA Institute for Human Data Science; 2023. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/assessing-the-biosimilar-void.

Car E, Vulto AG, Houdenhoven MV, Huys I, Simoens S. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends. Front Pharmacol. 2023;14:1151764.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aitken M. Global Use of Medicines 2023: Outlook to 2027 [Internet]. IQVIA Institute for Human Data Science; 2023. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-global-use-of-medicines-2023.

Vondeling GT, Cao Q, Postma MJ, Rozenbaum MH. The impact of patent expiry on drug prices: a systematic literature review. Appl Health Econ Health Policy. 2018;16:653–60.

Article  PubMed  PubMed Central  Google Scholar 

Beall RF, Ronksley PE, Wick J, Darrow JJ, Sarpatwari A, Kesselheim AS. Comparing onset of biosimilar versus generic competition in the United States. Clin Pharmacol Ther. 2020;108:1308–14.

Article  CAS  PubMed  Google Scholar 

Lee H-J, Han E, Kim H. Comparison of utilization trends between biosimilars and generics: lessons from the nationwide claims data in South Korea. Appl Health Econ Health Policy. 2020;18:557–66.

Article  PubMed  Google Scholar 

Vulto AG, Vanderpuye-Orgle J, Van Der Graaff M, Simoens SRA, Dagna L, Macaulay R, et al. Sustainability of biosimilars in Europe: a Delphi panel consensus with systematic literature review. Pharmaceuticals. 2020;13:400.

Article  PubMed  PubMed Central  Google Scholar 

Barros PP, Brouwer WBF, Thomson S, Varkevisser M. Competition among health care providers: helpful or harmful? Eur J Health Econ. 2016;17:229–33.

Article  PubMed  Google Scholar 

Lennox L, Linwood-Amor A, Maher L, Reed J. Making change last? Exploring the value of sustainability approaches in healthcare: a scoping review. Health Res Policy Syst. 2020;18:120.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alnaqbi KA, Bellanger A, Brill A, Castañeda-Hernández G, Clopés Estela A, Delgado Sánchez O, et al. An international comparative analysis and roadmap to sustainable biosimilar markets. Front Pharmacol. 2023;14:1188368.

Article  PubMed  PubMed Central  Google Scholar 

Aitken M. Advancing biosimilar sustainability in Europe [Internet]. IQVIA Institute for Human Data Science; 2018. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/advancing-biosimilar-sustainability-in-europe.

Bana A, Mehta PJ. Recognizing barriers to entry of biosimilars in the United States market and highlighting the solutions. J Generic Med Bus J Generic Med Sect. 2021;17:122–9.

Article  Google Scholar 

Whalen J. Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies. Am J Manag Care. 2020;26:S23-31.

Article  PubMed  Google Scholar 

FDA. Biosimilars—review and approval [Internet]. FDA; 2022 [cited 2025 Jan 16]. https://www.fda.gov/drugs/biosimilars/review-and-approval.

EMA. Biosimilar medicines: overview [Internet]. 2017 [cited 2025 Jan 16]. https://www.ema.europa.eu/en/human-regulatory-overview/biosimilar-medicines-overview.

Arato T. Japanese regulation of biosimilar products: past experience and current challenges. Br J Clin Pharmacol. 2016;82:30–40.

Article  PubMed  PubMed Central  Google Scholar 

Health Canada. Biosimilar Biologic Drugs in Canada: Fact Sheet [Internet]. Government of Canada; 2019. https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/fact-sheet-biosimilars.html#a5.

Grabowski HG, Guha R, Salgado M. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future. Health Aff (Millwood). 2014;33:1048–57.

Article  PubMed  Google Scholar 

Sen. Lee M [R-U. S.2305—118th Congress (2023–2024): Biosimilar Red Tape Elimination Act [Internet]. 2023 [cited 2024 Mar 21]. https://www.congress.gov/bill/118th-congress/senate-bill/2305/text.

US FDA. Labeling for Biosimilar and Interchangeable Biosimilar Products—Draft Guidance [Internet]. US Department of Health and Human Services; 2023. https://www.fda.gov/media/172170/download-

Vogler S, Schneider P, Zuba M, Busse R, Panteli D. Policies to encourage the use of biosimilars in European countries and their potential impact on pharmaceutical expenditure. Front Pharmacol. 2021;12: 625296.

Article  PubMed  PubMed Central  Google Scholar 

Tu SS, Goode R, Feldman WB. Biologic patent thickets and terminal disclaimers. JAMA. 2024;331:355.

Article  PubMed  Google Scholar 

Leber MB. Optimizing use and addressing challenges to uptake of biosimilars. Am J Manag Care. 2018;24:S457–61.

PubMed  Google Scholar 

Cardinal Health. 2024 Biosimilars Report: Insights on a pivotal year of evolution and expansion [Internet]. 2024. https://www.cardinalhealth.com/en/product-solutions/pharmaceutical-products/biosimilars/biosimilars-report.html-

Mulcahy A, Buttorff C. Projected US savings from biosimilars, 2021–2025. Am J Manag Care. 2022;28:329–35.

Article  PubMed  Google Scholar 

Mulcahy A, Hlavka J, Case S. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7:3.

PubMed  PubMed Central  Google Scholar 

Aladul MI, Fitzpatrick RW, Chapman SR. Impact of infliximab and etanercept biosimilars on biological disease-modifying antirheumatic drugs utilisation and NHS budget in the UK. BioDrugs. 2017;31:533–44.

Article  CAS  PubMed  Google Scholar 

Troein P, Newton M, Stoddart K, Arias A. The impact of biosimilar competition in Europe. IQVIA; 2022.

Patented Medicine Prices Review Board. Biologics in Canada. Part 2: biosimilar savings, 2018. Government of Canada; 2020.

Zhang C, Friedman S, Mruthyunjaya P, Parikh R. The biosimilar paradox. Ophthalmology. 2023;130:966–72.

Article  PubMed  Google Scholar 

Duggan B, Smith A, Barry M. Uptake of biosimilars for TNF-α inhibitors adalimumab and etanercept following the best-value biological medicine initiative in Ireland. Int J Clin Pharm. 2021;43:1251–6.

Article  CAS  PubMed  Google Scholar 

Mouslim MC, Trujillo AJ, Alexander GC, Segal JB. Association between filgrastim biosimilar availability and changes in claim payments and patient out-of-pocket costs for biologic filgrastim products. Value Health. 2020;23:1599–605.

Article  PubMed  PubMed Central  Google Scholar 

Edgar BS. Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative. J Manag Care Spec Pharm [Internet]. 2021;27. https://doi.org/10.18553/jmcp.2021.27.8.1129?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.

Baker JF, Leonard CE, Lo Re V, Weisman MH, George MD, Kay J. Biosimilar uptake in academic and veterans health administration settings: influence of institutional incentives. Arthritis Rheumatol. 2020;72:1067–71.

Article  PubMed  PubMed Central  Google Scholar 

Moorkens E, Barcina Lacosta T, Vulto AG, Schulz M, Gradl G, Enners S, et al. Learnings from regional market dynamics of originator and biosimilar infliximab and etanercept in Germany. Pharmaceuticals. 2020;13:324.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barcina Lacosta T, Vulto AG, Turcu-Stiolica A, Huys I, Simoens S. Qualitative analysis of the design and implementation of benefit-sharing programs for biologics across Europe. BioDrugs. 2022;36:217–29.

Article  PubMed